890839-78-8

Basic information

• Product Name: 1-(tert-Butyl)-2-((3-chloroprop-2-yn-1-yl)oxy)benzene
• Synonyms: 1-(tert-Butyl)-2-((3-chloroprop-2-yn-1-yl)oxy)benzene
• CAS NO: 890839-78-8
• Molecular Weight: 222.715
• Mol File: 890839-78-8.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 1-(tert-Butyl)-2-((3-chloroprop-2-yn-1-yl)oxy)benzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(tert-Butyl)-2-((3-chloroprop-2-yn-1-yl)oxy)benzene(890839-78-8)
• EPA Substance Registry System: 1-(tert-Butyl)-2-((3-chloroprop-2-yn-1-yl)oxy)benzene(890839-78-8)

Safety Data

• Hazardous Substances Data: 890839-78-8(Hazardous Substances Data)

Upstream product

• 88-18-6 2-tert-Butylphenol 
• 55619-88-0 1-(tert-butyl)-2-(prop-2-yn-1-yloxy)benzene 

Downstream Products

• 23067-79-0 8-(tert-Butyl)chroman-4-one 
• 1228553-77-2 C₁₃H₁₉NO 
• 1221444-51-4 (R)-8-tert-butylchroman-4-amine 

Relevant articles and documents

Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases

The invention provides modulators for the orphan nuclear receptor RORγ and methods for treating RORγ mediated diseases by administrating these novel RORγ modulators to a human or a mammal in need thereof. Specifically, the present invention provides pyrrolo sulfonamide compounds of Formula (1) and the enantiomers, diastereomers, tautomers, solvates and pharmaceutically acceptable salts thereof.

Chroman and tetrahydroquinoline ureas as potent TRPV1 antagonists

Novel chroman and tetrahydroquinoline ureas were synthesized and evaluated for their activity as TRPV1 antagonists. It was found that aryl substituents on the 7- or 8-position of both bicyclic scaffolds imparted the best in vitro potency at TRPV1. The most potent chroman ureas were assessed in chronic and acute pain models, and compounds with the ability to cross the blood-brain barrier were shown to be highly efficacious. The tetrahydroquinoline ureas were found to be potent CYP3A4 inhibitors, but replacement of bulky substituents at the nitrogen atom of the tetrahydroisoquinoline moiety with small groups such as methyl can minimize the inhibition.

TRPV1 ANTAGONISTS

Disclosed herein are compounds of formula (I), or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.